Hepion Pharmaceuticals Inc Analysis & Opinion (HEPA)

HEPA Analysis

This page features the latest analysis and reports for the Hepion Pharmaceuticals Inc stock.

6 Stocks That Could Pop Higher
- ByHarry Boxer
- •Jul 07, 2020
- 1
1. BioCryst BioCryst Pharmaceuticals (NASDAQ:BCRX), in the biotech vaccine area, on Tuesday popped to 5.41, up 46 cents, or 9%, after reaching a midday high of 5.56, on 10.9...
6 Stocks With More Room To Run
- ByHarry Boxer
- •Jun 24, 2020
- 1
1. Alpha Pro Tech Alpha Pro Tech (NYSE:APT) jumped 1.87, or 12%, to 17.48, on 10.8 million shares traded on Tuesday. This stock took off and has been running up the channel for...
Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge On Study Data
- ByZacks Investment Research
- •Jan 28, 2020
This week, quite a few biotech companies came out with pipeline and regulatory updates. Epizyme (NASDAQ:EPZM) got a significant boost with the FDA approval of its lead drug. Both...
Zacks.com Featured Highlights Include: JBGS, NWBI, THG, HEPA And HSII
- ByZacks Investment Research
- •Dec 22, 2019
For Immediate ReleaseChicago, IL – December 23, 2019 - Stocks in this week’s article are JBG SMITH Properties (NYSE:JBGS) , Northwest Bancshares, Inc. (NASDAQ:NWBI) ,...
Zacks.com Featured Highlights Include: NWBI, THG, RUBI, HEPA And KOF
- ByZacks Investment Research
- •Dec 11, 2019
For Immediate ReleaseChicago, IL – December 12, 2019 - Stocks in this week’s article are Northwest Bancshares, Inc. (NASDAQ:NWBI) , The Hanover Insurance Group, Inc....
Biotech ETFs Surge On A Flurry Of Positive News
- ByZacks Investment Research
- •Oct 22, 2019
The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities. This is especially true as the ultra-popular SPDR...
6 Stocks To Watch: CTRV, ENPH, PIRS, QD, TAL, ZYNE
- ByHarry Boxer
- •Jun 12, 2019
ContraVir Pharmaceuticals, Inc. (CTRV) CTRV has a long declining channel, but in the last week there has been a huge change of events in terms of volume. CTRV had an explosive...
ContraVir Pharmaceuticals: Possible Breakout Of Current Consolidation
- ByAntónio Costa
- •Nov 20, 2016
Contravir Pharmaceuticals Inc. (NASDAQ:CTRV) closed slightly below key resistance on volume. The technical daily chart above shows a large consolidating pennant shape that could...
4 Stocks To Watch: EXAS, NOVN, AAP, GIII
- ByHarry Boxer
- •Oct 18, 2016
It was another sloppy day on Wall Street and an ugly way to start the week. EXACT Sciences Corporation (NASDAQ:EXAS) had a big day on Monday. I really like the way it consolidated....

Name	Last	Chg. %	Vol.
TSLA	235.58	-1.36%	102.93M
AMZN	144.84	-1.49%	45.77M
NVDA	455.10	-2.68%	42.30M
AAPL	189.43	-0.95%	41.82M
MSFT	369.14	-1.43%	30.94M
META	320.02	-1.48%	18.64M
BRKa	542,380.00	-0.01%	10.13K

Name

Last

Chg. %

Vol.

TSLA

235.58

-1.36%

102.93M

AMZN

144.84

-1.49%

45.77M

NVDA

455.10

-2.68%

42.30M

AAPL

189.43

-0.95%

41.82M

MSFT

369.14

-1.43%

30.94M

META

320.02

-1.48%

18.64M

BRKa

542,380.00

-0.01%

10.13K

Name	Last	Chg. %	Vol.
BBWI	36.91	+8.91%	7.38M
IDXX	516.61	+7.05%	1.01M
NCLH	17.51	+6.64%	23.37M
EL	138.89	+5.27%	5.99M
ILMN	114.34	+4.14%	3.35M
VFC	18.79	+3.84%	11.05M
CCL	16.35	+3.74%	36.11M

Name

Last

Chg. %

Vol.

BBWI

36.91

+8.91%

7.38M

IDXX

516.61

+7.05%

1.01M

NCLH

17.51

+6.64%

23.37M

138.89

+5.27%

5.99M

ILMN

114.34

+4.14%

3.35M

VFC

18.79

+3.84%

11.05M

CCL

16.35

+3.74%

36.11M

Name	Last	Chg. %	Vol.
ALK	34.07	-14.25%	22.54M
SIRI	4.56	-6.56%	14.38M
ALB	119.90	-4.96%	3.33M
FCX	37.62	-4.14%	12.01M
TTD	68.76	-3.97%	6.81M
CRM	250.67	-3.59%	11.00M
RL	129.24	-3.29%	808.14K

Name

Last

Chg. %

Vol.

ALK

34.07

-14.25%

22.54M

SIRI

4.56

-6.56%

14.38M

ALB

119.90

-4.96%

3.33M

FCX

37.62

-4.14%

12.01M

TTD

68.76

-3.97%

6.81M

CRM

250.67

-3.59%

11.00M

129.24

-3.29%

808.14K

Name	Last	Chg. %	Vol.
TSLA	235.58	-1.36%	102.93M
NVDA	455.10	-2.68%	42.30M
COIN	141.09	+5.48%	21.24M
MSFT	369.14	-1.43%	30.94M
AAPL	189.43	-0.95%	41.82M

Name

Last

Chg. %

Vol.

TSLA

235.58

-1.36%

102.93M

NVDA

455.10

-2.68%

42.30M

COIN

141.09

+5.48%

21.24M

MSFT

369.14

-1.43%

30.94M

AAPL

189.43

-0.95%

41.82M

Hepion Pharmaceuticals is at the forefront of developing treatments for complex diseases like non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic conditions. The company uses Artificial Intelligence (AI) to drive its therapeutic drug development, which is a modern approach that could revolutionize treatment methodologies in the medical field. Promising Clinical Trial Results The company's lead drug, Rencofilstat, has shown promising results in the Phase 2 ALTITUDE-NASH clinical trial. This trial achieved primary and secondary endpoints, including improvement in liver function and multiple NASH biomarkers. Additionally, Hepion Pharmaceuticals announced major reductions in liver stiffness with Rencofilstat treatment in a 17-week Phase 2 study of advanced MASH liver disease. These positive outcomes from clinical trials are strong indicators of the drug's potential efficacy and success.
0
Be patient. keep waiting for 2 USD... it will keep going down with fake upward spikes
0
Let's think about it.. When they declared a split the price was 0.7 USD. They needed to hold a 1 USD level to stay in NASDAQ, they needed a +50% growth. They realized that they were not capable of that, which shows that they were aware that their future releases and updates were not going to be sufficient to attrack new investors. Therefore they use a split.. Because of this investors sold their shares and the price fell from 0.7 to 0.5. Then, after the split, it kept falling from 10 to 6, so the real value became 0.3 USD (a disaster). Once real investors sold, insiders and fishy traders decided to buy back the shares up to 20 USD...that is, up to the actual value of 1USD. Because of this alarming price without real suppor for it, now insiders are getting rid of these overvalued stocks selling them to newcomers who think that this is a growing company. Today the price is at 16 USD, that is, around 0.7 USD again. Would they buy more? No way, is an inflated stock, nobody wants to buy an inflated stock without a solid future... Thanks to this move we already know that a good entry point is 6 USD, but due to global consequences it must drop to 2 USD... 2 USD is a good starting point to reset this company from scratch..so until then let's wait
0
Dont buy this... now is at 10 USD after a split 1:20.. real value is 0.5 USD. It will never jump back to 20 USD, HEPA is meant to go back to 2 USD in the future, you will waste money here :D. Every company that splits to remain in NASDAQ fails to increase. of course in the short term it may jump back to 12 or even 15 but the ultimate value in this season is 2 USD... so a total waste....
0
Split reflects that they don't have money nor good results in the coming months to reach the 0.1USD threshold... In simple terms "they suc$k". Sell their trash. Come back when they are back to 2USD...downtrend is so
0
hepion's comeback
0
- any reason?
  0
- they got a nofitication to reach the minium value of 1USD..otherwise they are out of NASDAQ. so they will try to remain above 1... you can read all on their website
  0
1.05 is quite delicious :)
0
Why is it showing 0.627? This stock closed at 1.59.
0
Another offering up for vote, bad news
0
Hepion was supposed to release treatment results in February and they never did. I suggest to newcomers...don't invest here. They lost credibility by missing deadlines. Moreover, investors bought at 2.00 and they are losing. Just wait for news to come in its website then you are welcome to come. Daytraders are likely winning because the oscillations here are so rewarding if you focus on profiting from the continous downtrend, don't wait for miracles in the long term until you have solid news. Cheers
0

Popular Searches

Please try another search

Hepion Pharmaceuticals Inc (HEPA)

HEPA Analysis

Trending Stocks